Incyte (INCY) Misses Q1 EPS by 18c ; Offers Guidance

Incyte (NASDAQ: INCY) reported Q1 EPS of $0.64, $0.18 worse than the analyst estimate of $0.82. Revenue for the quarter came in at $880.89 million versus the consensus estimate of $925 million.

GUIDANCE:

Incyte sees FY2024 revenue of $2.69-2.75 billion, versus the consensus of $4.12 billion.

For earnings history and earnings-related data on Incyte (INCY) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
• Moody’s raises BJ’s Wholesale outlook to positive on debt reduction